The chief executive of embattled Valeant Pharmaceuticals has agreed to be deposed by a Senate committee investigating soaring prescription medicine prices.
Meanwhile, the Canadian drugmaker has received a notice of default from some bond holders because it hasn't filed its 2015 financial report, which was due in March.
Valeant CEO agrees to be deposed in Senate drug price probe
Aucun commentaire:
Enregistrer un commentaire